QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements

HILDEN, Germany, and GERMANTOWN, Maryland, January 8, 2018 /PRNewswire/ --

• Goal set to exceed $140 million of NGS-related sales in 2018, up from over $115 million in 2017 
• New Enterprise Genomics Services to offer gene panel customization capabilities to customers 
• GeneReader NGS System plans include enhanced chemistry, more powerful gene panels  

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a range of product and service enhancements to its next-generation sequencing (NGS) portfolio, which offers universal solutions for use with any NGS sequencer as well as the GeneReader NGS System*, the world's first complete Sample to Insight solution based on proprietary chemistry that makes the benefits of NGS accessible to any laboratory. QIAGEN has set a goal to exceed $140 million in 2018 sales from this portfolio, up from over $115 million in 2017.

These initiatives, which include the launch of a new Enterprise Genomics Services offering to customers for the customization of gene panels, are designed to add momentum to QIAGEN's rapidly growing presence in NGS, a technology that is enabling valuable molecular insights along the continuum from basic academic research to routine clinical healthcare.

"QIAGEN's presence in next-generation sequencing continues to grow at a strong double-digit rate for sales, fueled by innovative solutions for faster and better results on any NGS platform as well as by the rapid adoption of our GeneReader NGS System," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "Our expansion plans for 2018 include the rapid scale-up of the new Enterprise Genomics Services, which will help customers to accelerate and de-risk the development of new gene panels that are essential for the migration of biomedical findings from discovery to implementation in clinical healthcare. We also have extensive growth plans for our successful GeneReader system with the introduction of the new, proprietary third-generation chemistry and a series of new gene panels based on our proprietary Digital NGS technology."

* For research use only

Click here for full press release: https://corporate.qiagen.com/newsroom/press-releases/2017/20180108_NGS_Portfolio_Expansion?sc_lang=en

Contacts: 

QIAGEN 

Investor Relations 
John Gilardi 
+49-2103-29-11711

e-mail:[email protected]

Public Relations
Dr. Thomas Theuringer

+49-2103-29-11826

e-mail: [email protected]

SOURCE Qiagen N.V.